Datapoint: Pfizer Scores Endometriosis Nod for Myfembree

The FDA last week approved Pfizer’s Myfembree for the treatment of moderate to severe endometriosis pain in pre-menopausal women. The once-daily pill was first approved for the treatment of uterine fibroids in May 2021. For this indication, the drug currently holds covered or better status for 80% of all insured lives, with 44.8% having preferred access to Myfembree.

SOURCE: MMIT Analytics, as of 8/10/22

0 Comments
Carina Belles

Carina Belles

Carina is a reporter at AIS, specializing in public sector data research, trend analysis and infographics. She holds a Bachelor of Science in Journalism from Ohio University, joining AIS shortly after graduating in 2014.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 7

Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today